Neumora Therapeutics (NASDAQ:NMRA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research note issued to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

NMRA has been the subject of several other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a report on Wednesday. Finally, JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.67.

Neumora Therapeutics Stock Down 4.7 %

Shares of Neumora Therapeutics stock opened at $10.78 on Wednesday. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -5.91 and a beta of 3.92. Neumora Therapeutics has a 52-week low of $8.33 and a 52-week high of $21.00. The company’s 50-day simple moving average is $13.08 and its 200-day simple moving average is $11.41.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.07). During the same period in the prior year, the business posted ($1.14) earnings per share. Equities research analysts anticipate that Neumora Therapeutics will post -1.48 EPS for the current year.

Insider Buying and Selling

In other Neumora Therapeutics news, CFO Joshua Pinto sold 31,642 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $11.78, for a total transaction of $372,742.76. Following the completion of the transaction, the chief financial officer now directly owns 154,658 shares in the company, valued at approximately $1,821,871.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Joshua Pinto sold 31,642 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $11.78, for a total value of $372,742.76. Following the sale, the chief financial officer now owns 154,658 shares of the company’s stock, valued at approximately $1,821,871.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total value of $363,606.28. Following the sale, the insider now owns 339,205 shares in the company, valued at approximately $4,006,011.05. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 110,538 shares of company stock worth $1,390,513 in the last three months. Corporate insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Artal Group S.A. raised its holdings in Neumora Therapeutics by 14.5% in the 1st quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock valued at $40,206,000 after acquiring an additional 371,350 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Neumora Therapeutics in the first quarter valued at $10,354,000. Charles Schwab Investment Management Inc. increased its stake in Neumora Therapeutics by 139.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after purchasing an additional 406,891 shares during the last quarter. Callan Capital LLC lifted its position in Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after buying an additional 456,207 shares during the period. Finally, Baker BROS. Advisors LP purchased a new position in Neumora Therapeutics during the first quarter worth about $8,715,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.